LillyDirect
Is LillyDirect listed in FDA warning letters?
No FDA warning letters addressed to LillyDirect appear in our dataset (FDA.gov letters 2023–2026). FDA has issued 3 warning letters to the manufacturer, Eli Lilly and Company: 2025-09-09, 2025-09-09, 2025-09-09. Subject named in the FDA records: "False & Misleading Claims/Misbranded".
Key facts
- •Care model: Manufacturer self-pay and access program.
- •Medications discussed: Zepbound (tirzepatide), Foundayo (orforglipron).
- •State availability: Confirm directly with program. Note: The reviewed program page did not provide a state availability list. Confirm pharmacy access directly.
Manufacturer self-pay program for Zepbound. A valid prescription is required; prescriber services are not represented as included.
- At a glance
- Care model
- Manufacturer self-pay program
- Medications discussed
- Zepbound (tirzepatide), Foundayo (orforglipron)
- Availability
- Confirm with program
FDA Warning Letter Records Identified
LillyDirect is the direct-to-consumer pharmacy and clinical fulfillment portal operated by manufacturer Eli Lilly and Company. Official FDA warning letters issued to the parent manufacturer concerning direct-to-consumer promotional video communications are detailed below.
Eli Lilly and Company
Center for Drug Evaluation and Research (CDER)
Subject: False & Misleading Claims/Misbranded
FDA says a direct-to-consumer video was false or misleading because it omitted and minimized serious risks of Zepbound and Mounjaro, including the boxed warning and contraindications, and that the video was not submitted to FDA on Form FDA-2253 at initial dissemination.
Eli Lilly and Company
Center for Drug Evaluation and Research (CDER)
Subject: False & Misleading Claims/Misbranded
FDA says a promotional video for Zepbound omitted all risk information and limitations of use, creating a misleading impression of the drug's safety and approved use, and that the video was not submitted to FDA on Form FDA-2253 at initial publication.
Eli Lilly and Company
Center for Drug Evaluation and Research (CDER)
Subject: False & Misleading Claims/Misbranded
FDA says a sponsored online video promoting Zepbound omitted all risk information and the drug's limitations of use, creating a misleading impression of safety and approved use, and was not submitted to FDA under Form FDA-2253 when initially published.
Before you use this program
This is a manufacturer self-pay program for filling a prescription, not a care program. Read its terms on its own website.
- •Is a prescription from your own clinician required?
- •Which pharmacy fills the prescription, and how is it delivered?
- •Who do you contact with questions about an order?
Source records
Evaluate Eligibility & Coverage Before Enrolling in LillyDirect
Check manufacturer copay card rules, federal program exclusions, and cash-pay vial terms for LillyDirect.
Copay & Savings Card Rules
Model out-of-pocket copays for Zepbound and Wegovy under commercial plans ($25/mo caps) vs. self-pay cash channels.
Baseline Lab & Safety Screen
Legitimate telehealth prescribers require baseline kidney and A1c bloodwork. Review required panels and boxed warnings before your intake.
FDA BMI Indication Gauge
Verify whether your BMI meets official FDA prescribing standards (BMI ≥30 or ≥27 with comorbidity) before paying non-refundable fees.
Telehealth Navigation & Checklist
Evaluating a digital clinic? Review our clinical checklists for verifying state licensure, required blood work, and navigating insurance coverage.
How to Spot a Legit Clinic
Physician NPI checks, state licensing, and avoiding online scams.
How to Get a Prescription
Step-by-step telehealth workflow, required labs, and BMI criteria.
Prior Authorization Guide
Commercial insurance criteria, clinical documentation, and appeals.